GI tract

Teduglutide listed on PBS for Short Bowel Syndrome

Wednesday, 2 Oct 2019

Patients with intestinal failure associated with Short Bowel Syndrome (SBS), will have access to PBS-subisdised teduglutide (Revestive) from 1 October.

The medication, which improves the absorption of nutrients and fluid from the gut, is expected to be accessed by up to 70 patients per year who would otherwise face costs of up to $284,700 per year for treatment.

When recommended for approval for PBS listing at its May 2019 meeting, the by the Pharmacetical Benefits Advisory Committee said there was a high clinical need for an effective therapy that reduces the patient burden associated with parenteral support.

The committee made its recommendation conditional on restrictions to ensure that teduglutide treatment is confined to those patients most likely to achieve a clinically meaningful benefit, and with the treatment duration limited to that necessary to achieve meaningful benefits.

The conditions limit use of teduglutide to patients who have a history of dependence on parenteral support for at least 12 months, require ≥ 3 days per week of parenteral support, and have stable parenteral support requirements for at least four consecutive weeks prior to initiating teduglutide. They also include a stopping rule with a ‘trial of treatment cessation’ for patients whose parenteral support becomes stable.

Already a member?

Login to keep reading.

Email me a login link

© 2022 the limbic